HomeGeneticsConditionAspartylglucosaminuria
Back to Condition
Aspartylglucosaminuria
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Aspartylglucosaminuria

Aspartylglucosaminuria is a rare, progressive genetic condition that primarily affects mental functioning and movement, worsening from early childhood into adulthood.

Overview

Aspartylglucosaminuria is a condition that primarily affects mental functioning and movement. This condition worsens over time. Infants with aspartylglucosaminuria appear healthy at birth, and development is typically normal throughout early childhood.

Symptoms

Signs and symptoms of aspartylglucosaminuria develop and change as an individual ages:

Early Childhood

  • Delayed speech and mild intellectual disability, typically beginning around age 2 or 3
  • Problems coordinating movements
  • Frequent respiratory infections
  • Hernias, which are protrusions of organs through gaps in muscles
  • A growth spurt resulting in a large head size (macrocephaly)
  • Children may be tall for their age

Adolescence and Adulthood

  • Worsening intellectual disability and movement problems
  • Loss of much of the speech learned in childhood, with affected adults usually having only a few words in their vocabulary
  • Psychological disorders
  • Development of seizures
  • Short stature and a small head size (microcephaly) due to a lack of a growth spurt in puberty

Other Physical Features

  • Bones that become progressively weak and prone to fracture
  • An unusually large range of joint movement (hypermobility)
  • Loose skin
  • A characteristic facial appearance that includes widely spaced eyes, full lips, and a square-shaped face
  • Poor oral health, including infections and gum disease (gingivitis)

Individuals with aspartylglucosaminuria usually survive into mid-adulthood.

Frequency

In Finland, it is estimated that 1 to 3 individuals are born with aspartylglucosaminuria each year. This condition is less common outside of Finland, but the incidence is unknown.

Causes

Variants (also known as mutations) in the AGA gene cause aspartylglucosaminuria. The AGA gene provides instructions for producing an enzyme called aspartylglucosaminidase. This enzyme is active in lysosomes, which are structures inside cells that act as recycling centers. Within lysosomes, the enzyme helps break down complex chains of sugar molecules (oligosaccharides) attached to certain proteins (glycoproteins).

AGA gene variants result in a lack (deficiency) of the aspartylglucosaminidase enzyme in lysosomes, preventing the normal breakdown of glycoproteins. As a result, glycoproteins can build up within the lysosomes. Excess glycoproteins disrupt the normal functions of the cell and can result in cell death. A buildup of glycoproteins seems to particularly affect nerve cells in the brain; loss of these cells causes many of the signs and symptoms of aspartylglucosaminuria.

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have variants. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • AGA deficiency
  • Aspartylglucosamidase deficiency
  • Aspartylglucosaminidase deficiency
  • Aspartylglycosaminuria
  • Glycosylasparaginase deficiency

Frequently Asked Questions

Since AGA mutations follow an autosomal recessive inheritance pattern, each pregnancy carries a 25 % risk of an affected child if both parents are carriers. Carrier testing for siblings and extended family members is recommended. Couples may consider pre‑implantation genetic diagnosis (PGD) or prenatal testing (chorionic villus sampling or amniocentesis) to make informed reproductive decisions.
Clinicians should consider AGA deficiency when a child older than 2 years shows delayed speech, mild intellectual disability, frequent respiratory infections, and a noticeable increase in head circumference (macrocephaly) or early tall stature. The presence of joint hypermobility, hernias, or a characteristic facial appearance (wide‑set eyes, full lips, square face) strengthens suspicion. Confirmatory testing includes urine oligosaccharide analysis and sequencing of the AGA gene.
Currently, no enzyme replacement or gene therapy is approved. Management focuses on supportive care: regular physiotherapy to maintain joint range, respiratory physiotherapy to reduce infections, and early educational interventions. Some experimental approaches, such as substrate reduction therapy, are under investigation but remain unavailable outside clinical trials.
Speech‑language pathologists should transition patients to low‑technology AAC devices (e.g., picture boards) and later to speech‑generating devices as verbal ability wanes. Mobility support includes customized orthotics, gait trainers, and, when needed, powered wheelchairs. Regular assessments by a multidisciplinary team allow timely adjustments to equipment and therapy intensity.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab